NeuBase Therapeutics, Inc. Common Stock
NBSE
NBSE was delisted on the 10th of May, 2024.
50 hedge funds and large institutions have $51M invested in NeuBase Therapeutics, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 13 increasing their positions, 15 reducing their positions, and 12 closing their positions.
2% more funds holding
Funds holding: 49 → 50 (+1)
8% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 12
1% less capital invested
Capital invested by funds: $51.5M → $51M (-$568K)
13% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.43M |
| 2 |
FWM
Frontier Wealth Management
Kansas City,
Missouri
|
+$1.18M |
| 3 |
SCM
Sio Capital Management
New York
|
+$1.02M |
| 4 |
GC
Greenlight Capital
New York
|
+$1.01M |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$788K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$3.68M |
| 2 |
Renaissance Technologies
New York
|
-$2.77M |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
-$756K |
| 4 |
Two Sigma Advisers
New York
|
-$216K |
| 5 |
BlackRock
New York
|
-$215K |
NBSE Hedge Fund Activity: Q3 2020 in Review
50 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q3 2020, worth a combined $51M — down 1.1% from $51.5M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new NBSE positions and 12 closed out — a net gain of 1 holder — while 13 added to existing stakes and 15 trimmed.
The largest buyer was Vanguard Group, adding an estimated $6.43M. The largest seller was Millennium Management, exiting entirely with an estimated $3.68M sold.
- 50 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q3 2020, up from 49 in Q2 2020.
- Funds reported $51M of NeuBase Therapeutics, Inc. Common Stock stock for Q3 2020, down 1.1% quarter-over-quarter.
- 13 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q3 2020 and 12 closed out, a net change of +1 holder.
- The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q3 2020 was Vanguard Group, an estimated $6.43M added.
- The largest NeuBase Therapeutics, Inc. Common Stock seller in Q3 2020 was Millennium Management, an estimated $3.68M sold.
Based on aggregated 13F filings for Q3 2020.